Table 2. Comparison of ARTESIA and NOAH trials.

Study	Identifier	Inclusion criteria	Number of patients	Design	Endpoint	Current status	Estimated completion date
ARTESIA9	Clinicaltrials.gov NCT01938248	Patients without clinical AF Pacemaker, ICD or CRT Age ≥ 65 years CHA2DS2-VASc score ≥ 4 1 episode of symptomatic AF ≥ 6 min, atrial rate > 175 bpm no single episode > 24 h in duration	4000	Randomised, doubleblind, double-dummy Randomised to Apixaban 2 × 5 mg or 2 × 2.5 mg vs aspirin 1 × 81 mg	Composite of stroke and SSE Major bleeding	Recruiting	2022
NOAH AFNET 610	Clinicaltrials.gov NCT02618577	Only patients without overt AF Pacemaker or ICD Age ≥ 65 years CHA2DS2-VASc ≥ 2 ≥ 1 episode of AHRE . 6 min, atrial rate > 180 bpm, no single episode > 24 h	2686	Randomised, doubleblind double-dummy Edoxaban 1 × 60 mg or 1 × 30 mg vs 1 × aspirin 100 mg or placebo	Composite of time to first stroke, SSE or CV death	Recruiting	2022

AF, atrial fibrillation; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronisation therapy; SSE, systemic embolism.